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Recurrent bloodstream infections caused by a Gram-positive bacterium affected an immunocompromised child. Tsukamurella
pulmonis was the microorganism identified by secA1 gene sequencing. Antibiotic treatment in combination with removal of the
subcutaneous port healed the patient.
CASE REPORT
A3-year-old female was diagnosed with acute lymphoblasticleukemia (ALL), with intermediate risk (immunophenotype
pre-B), when she was 23 months old. In order to start her chemo-
therapy, a central venous access device (subcutaneous port [SP])
was implanted in September 2009. The patient was treated with
SHOP-05 (Spanish Pediatric Hematology Society-2005) proto-
cols for high-risk ALL, and she was in complete remission after the
induction phase and completed four consolidation and reinduc-
tion phases, as was mandatory. Near the end of the second year of
maintenance, when she was receiving only oral mercaptopurine
(50 mg/m2/daily) and intramuscular methotrexate (20 mg/m2/
weekly), the patient had a fever peak 5 h after a blood collection
from the SP. The patient was treated empirically with oral cefixime
(8 mg/kg of body weight/daily) when the fever started because she
had had a prior isolation documented as Klebsiella pneumoniae
that was sensitive to cephalosporins, and since she was not neu-
tropenic and had no other signs or symptoms of interest, outpa-
tient management was tried first. We obtained one pediatric blood
culture, which grew long, slightly curved, thin, nonbranching
Gram-positive rods. Culture of blood samples after 48 h of incu-
bation at 35°C  2°C in 5% CO2 on chocolate and blood agar
showed small, rough, whitish colonies which did not produce aer-
ial mycelium. The biochemical profile of the isolate obtained with
the API Coryne identification system (bioMérieux, Marcy l’Etoile,
France) after 48 h of incubation (2150004) corresponded to Rho-
dococcus spp. at a confidence level of 82.9%. By sequencing the 16S
rRNA gene with the universal primers PA (5=-AGAGTTTGATCC
TGGCTCAG-3=) and PLO6R (5=-GCGCTCGTTGCGGGACTTA
ACC-3=) and the internal primer UP1R (5=-TTACCGCGGCTGC
TGGCAC-3=), we obtained a sequence of 1,025 nucleotides that
revealed maximal identity with Tsukamurella pulmonis (GenBank
accession number AB564289). However, the 16S rRNA gene se-
quences of different Tsukamurella spp. were shown to be quite
similar (99%).
Two weeks later, due to the persistence of intermittent fever in
spite of cefixime therapy and two subsequent blood culture sets
again positive for the same bacterium (T. pulmonis), the patient
was admitted to the hospital. Antibiotic susceptibility was deter-
mined after 48 to 72 h of incubation at 35°C  2°C in ambient air
by gradient diffusion (Etest; bioMérieux, Marcy l’Etoile, France)
using Mueller-Hinton agar plates. Interpretations were based on
CLSI breakpoints for mycobacteria, nocardiae, and other aerobic
actinomycetes but not breakpoints for meropenem (MIC  32
g/ml) and vancomycin (MIC, 2 g/ml) because they were not
assessed in this document. The isolate was susceptible to amikacin
(MIC, 1 g/ml), tobramycin (MIC, 4 g/ml), ciprofloxacin (MIC,
0.25 g/ml), clarithromycin (MIC, 0.125 g/ml), and linezolid
(MIC, 1 g/ml) and resistant to amoxicillin-clavulanic acid
(MIC  256 g/ml) and ceftriaxone (MIC  32 g/ml).
For 3 days, she received ertapenem intravenously (15 mg/kg/12
h), but due to both the onset of a generalized nonpruriginous rash
and the results of susceptibility testing, ciprofloxacin (20 mg/kg/
day in 2 doses) and amikacin (20 mg/kg/day) were then pre-
scribed; the catheter was removed on the fourth day of admission.
The patient improved and remained afebrile 24 h after treatment
change and device removal. The treatment was completed after 7
days of ciprofloxacin and amikacin administration, and after-
wards, she was treated with oral clarithromycin (15 mg/kg/day in
two doses) for 15 days in her home. The device was sent for mi-
crobiological culture, but no growth was observed on brain heart
infusion medium. No clinical relapse was observed during the
next year, and she remains in complete uneventful remission.
In order to confirm T. pulmonis identification, additional phe-
notypic and molecular tests were performed. The isolate did not
grow at 42°C, and the following results of sugars assimilation were
obtained with the API 50 CH systems (bioMérieux, Marcy l’Etoile,
France). The isolate was mannitol positive, inositol negative, D-
sorbitol negative, arbutin negative, inulin negative, D-melezitose
negative, D-arabitol negative, and L-fucose positive. The available
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partial secA1 gene sequences of three Tsukamurella species (depos-
ited by researchers at Westmead Hospital in Sydney, Australia),
namely, Tsukamurella tyrosinosolvens (GenBank accession num-
ber GU179146), Tsukamurella pseudospumae (GU179143), and
Tsukamurella pulmonis (GU179144), and the complete secA1 se-
quence of the Tsukamurella paurometabola type strain, ATCC
8368 (CP001966), were aligned by using the Clustal W program
(v. 1.81). Two candidate primers, Tsuka1 (5=-CTACCTGCGCGA
CAACATG-3=) and Tsuka2 (5=CGATCGTCTTCTTGCGGATG-
3=), which correspond to T. paurometabola secA1 gene positions
546 to 564 and 756 to 775, respectively (GenBank accession no.
CP001966, nucleotides 1106448 to 1109201), were designed by
using primer 3.
The PCR amplification of the secA1 gene of our isolate
(HUMV-11090126) (annealing temperature of 60°C) showed the
predicted amplicon of 230 bp. Subsequent sequencing with the
same primers and comparison of the obtained sequence with
GenBank entries, by using the BLASTn algorithm, gave 98%
homology with T. pulmonis (accession no. GU179144), followed
by T. pseudospumae (GU179143) (91.7%), T. tyrosinosolvens
(GU179145, GU179146, GU179147, GU179148, GU179149)
(91.2%), and T. paurometabola (CP001966) (90.4%) (Table 1).
The genus Tsukamurella includes aerobic Gram-positive and
modified acid alcohol-fast-positive rods belonging to the aerobic
actinomycetes, usually found in soil, sludge, and arthropods (1).
Yassin et al. isolated and described the species of interest, T.
pulmonis, in 1996 from the sputum of a 92-year-old woman with
a history of lung tuberculosis (2).
T. pulmonis is a rare human pathogen associated with onco-
logic and immunosuppressed patients (3, 4), and a variety of in-
fections have been associated with this bacterium: pneumonia (5),
conjunctivitis (6), keratitis (7), and catheter-related bacteremia
(3, 8). In our case, T. pulmonis was isolated from an immunosup-
pressed child in three different blood culture sets, but the primary
source of the infection could not be identified. Even though the
long-term central venous catheter culture was negative, the first
fever peak was registered after blood was collected for a hemato-
logical analysis, and the patient improved as the catheter was re-
moved. In consequence, it seems reasonable to consider this de-
vice associated with the beginning of episodes. Bouza et al. (9)
performed a review of catheter-related bloodstream infections,
and most of them required the withdrawal of the infected line,
along with antibiotic treatment, to resolve the episodes.
Our isolate was susceptible to aminoglycosides, macrolides,
and quinolones but resistant to amoxicillin-clavulanic acid, ceftri-
axone, and presumably carbapenems. Other authors have shown a
similar susceptibility pattern (3, 4, 10).
T. pulmonis and related species may well be underdiagnosed or
misdiagnosed as a cause of significant infections owing to the dif-
ficulty of identifying the organism by phenotypic procedures (11).
Two reports (4, 9) have described the same API Coryne code
which we found for our isolate.
Aimed at identifying uncommon pathogens, most of all in im-
munocompromised hosts, 16S rRNA sequencing is a reasonably
rapid and consistent molecular technique. However, in this case,
the gene was not shown to be discriminative enough for the iden-
tification of Tsukamurella spp., since the differences in the genes
are minimal among the different species of the genus (Table 1)
(9, 10). In contrast, an analysis of a region of the secA1 gene was
shown to be suitable for discrimination among four important
clinical species of Tsukamurella, as it has been demonstrated for
other clinically significant species of aerobic actinomycetes
(12, 13).
We could not perform a comparison with Tsukamurella
strandjordii and Tsukamurella inchonensis, the other species re-
covered from clinical specimens, because their sequences have not
been deposited in GenBank.
Nevertheless, in our case, the isolate could be differentiated
from T. inchonensis because our species does not grow at 45°C and
from T. strandjordii on the basis of its sugar utilization profile,
since T. strandjordii uses inulin, arbutin, and D-melezitose as car-
bon sources, whereas our isolate does not (14, 15).
In conclusion, we present a case of bacteremia caused by T.
pulmonis that was essentially identified by molecular methods, in
particular, secA1 gene sequencing, and this gene was demon-
TABLE 1 Sequence similarity values for 16S rRNA sequences and secA1 sequences of Tsukamurella species and our clinical isolate of T. pulmonis,
HUMV-11090126a
Tsukamurella species


















































T. paurometabola 91.5 90.4 ND 90 90.4
T. pseudospumae 99 96 ND 93.4 91.7
T. tyrosinosolvens 99.3 99.5 ND 92.1 91.2
T. strandjordii 99.5 99.3 99.7 ND ND
T. pulmonis 99.5 99.6 99.7 99.5 98
HUMV-11090126b 99.6 99.6 99.7 99.7 100
a 16S rRNA sequences are in the lower left, and secA1 sequences are in the upper right. ND, no data. 16S rRNA GenBank accession numbers were as follows: for T. paurometabola,
NR074458; for T. pseudospumae, NR042800; for T. tyrosinosolvens, AY238514; for T. strandjordii, AF283283; and for T. pulmonis, AY741505 (the accession number for the secA1
gene sequences are indicated in the text).
b The 16S rRNA is 1,012 bp; the secA1 gene is 230 bp.
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strated to be a good target for differentiation among the most
relevant pathogenic species of this genus.
Nucleotide sequence accession numbers. The 16S rRNA se-
quence and the secA1 sequence of the T. pulmonis isolate were
deposited in GenBank under accession numbers KP056257 and
KP013182, respectively.
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